Real-world data of dacomitinib as first-line treatment for patients with EGFR-mutant non-small-cell lung cancer

Real-world data of dacomitinib as first-line treatment for patients with EGFR-mutant non-small-cell lung cancer

Abstract Dacomitinib demonstrated superior survival benefit compared to gefitinib as a first-line treatment in non-small cell lung cancer (NSCLC) patients with common EGFR mutations through ARCHER 1050. However, there is limited real-world data concerning its efficacy and safety. This study included...

Full description

Saved in:
Bibliographic Details
Main Authors: Ji Eun Shin, Hyun Ae Jung, Sehhoon Park, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Myung-Ju Ahn, Byoung Yong Shim
Format: Article
Language:English
Published: Nature Portfolio 2025-02-01
Series:Scientific Reports
Subjects:
Epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC)
Dacomitinib
Real-world data
Online Access:https://doi.org/10.1038/s41598-024-81704-4
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41598-024-81704-4

Similar Items